Fred Gebhart, Contributing Editor
Contributing Editor Fred Gebhart works all over the world as a freelance writer and editor, but his home base is in San Francisco.
Medicaid can learn from the World Health Organization
Medicaid formularies cost more than the WHO's Model List of Essential Medicines.
House hearings open Express Scripts-Medco merger battle
The debate over the proposed merger between Express Scripts Inc. and Medco has hit the House of Representatives.
Medco and Express Scripts: Could this merger put your business at risk?
Express Scripts' proposed acquisition of Medco Health Solutions has generated more headlines than agreement. Medco and ESI love the deal. Retail pharmacy wants to scuttle it. And FTC is asking questions.
Generics continue to roll up medication markets
Big Pharma is going on an involuntary diet this year.
California association launches ombudsman program
The California Pharmacists Association is launching what may be the nation's first ombudsman program run through a professional association.
Data-mining uncovers hyperglycemic drug-drug interaction between paroxetine and pravastatin
Bioinformatics researchers at Stanford University have uncovered a never-before-reported drug-drug interaction between pravastatin and paroxetine.
Rite Aid, skin cancer group launch sun safety campaign
Rite Aid Corporation and the Skin Cancer Foundation have launched a new healthy skin-care campaign offering free information online and in all Rite Aid stores to consumers, and increased professional information to the chain's pharmacists.
Oncology drug shortage raises safety concerns
Continuing shortages of generic oncology chemotherapeutic agents dangerously limit patient-care choices, affect clinical outcomes, and stretch already tight pharmacy resources.
Antipsychotics overused in LTC setting, OIG says
Long-term-care facilities are overusing antipsychotic drugs. One of every 7 elderly nursing home residents is receiving at least 1 atypical antipsychotic.
California misses Medicaid rebate on compound drug claim
California has failed to bill drug manufacturers for nearly $30 million in rebates due on compound drugs dispensed through the state Medicaid program, known as MediCal.